Verrica Expands YCANTH Sales as Wart Trials Advance
WEST CHESTER, PA — Verrica Pharmaceuticals Inc. (Nasdaq: VRCA) reported higher first-quarter revenue and accelerating demand for its YCANTH treatment as the company advances late-stage clinical trials that could significantly …
Verrica Expands YCANTH Sales as Wart Trials Advance Read More